



Deficiency of the sphingosine-1-phosphate (S1P) transporter Mfsd2b protects the heart against hypertension-induced cardiac remodeling by suppressing the L-type-Ca²⁺ channel

Dragos Andrei Duse^{1,2,3} · Nathalie Hannelore Schröder¹ · Tanu Srivastava⁴ · Marcel Benkhoff² · Jens Vogt¹ · Melissa Kim Nowak¹ · Florian Funk⁴ · Nina Semleit¹ · Philipp Wollnitzke¹ · Ralf Erkens^{2,3} · Sebastian Kötter⁵ · Sven Günther Meuth⁶ · Petra Keul¹ · Webster Santos⁷ · Amin Polzin^{2,3} · Malte Kelm^{2,3} · Martina Krüger^{3,5} · Joachim Schmitt^{3,4} · Bodo Levkau^{1,3}

Received: 25 April 2024 / Revised: 26 July 2024 / Accepted: 29 July 2024 / Published online: 7 August 2024
© The Author(s) 2024

Abstract

The erythrocyte S1P transporter Mfsd2b is also expressed in the heart. We hypothesized that S1P transport by Mfsd2b is involved in cardiac function. Hypertension-induced cardiac remodeling was induced by 4-weeks Angiotensin II (AngII) administration and assessed by echocardiography. Ca²⁺ transients and sarcomere shortening were examined in adult cardiomyocytes (ACM) from Mfsd2b^{+/+} and Mfsd2b^{-/-} mice. Tension and force development were measured in skinned cardiac fibers. Myocardial gene expression was determined by real-time PCR, Protein Phosphatase 2A (PP2A) by enzymatic assay, and S1P by LC/MS, respectively. Mfsd2b was expressed in the murine and human heart, and its deficiency led to higher cardiac S1P. Mfsd2b^{-/-} mice had regular basal cardiac function but were protected against AngII-induced deterioration of left-ventricular function as evidenced by ~30% better stroke volume and cardiac index, and preserved ejection fraction despite similar increases in blood pressure. Mfsd2b^{-/-} ACM exhibited attenuated Ca²⁺ mobilization in response to isoprenaline whereas contractility was unchanged. Mfsd2b^{-/-} ACM showed no changes in proteins responsible for Ca²⁺ homeostasis, and skinned cardiac fibers exhibited reduced passive tension generation with preserved contractility. Verapamil abolished the differences in Ca²⁺ mobilization between Mfsd2b^{+/+} and Mfsd2b^{-/-} ACM suggesting that S1P inhibits L-type-Ca²⁺ channels (LTCC). In agreement, intracellular S1P activated the inhibitory LTCC phosphatase PP2A in ACM and PP2A activity was increased in Mfsd2b^{-/-} hearts. We suggest that myocardial S1P protects from hypertension-induced left-ventricular remodeling by inhibiting LTCC through PP2A activation. Pharmacologic inhibition of Mfsd2b may thus offer a novel approach to heart failure.

Keywords Sphingosine-1-phosphate · Left-ventricular remodeling · Cardioprotection · Mfsd2b

Abbreviations

ACM Adult cardiomyocytes
AngII Angiotensin II
BDM 2,3-Butanedione monoxime

Ca²⁺ Calcium
DTT Dithiothreitol
EC Endothelial cells
ECM Extracellular matrix

✉ Bodo Levkau
bodo.levkau@med.uni-duesseldorf.de

¹ Institute for Molecular Medicine III, University Hospital Düsseldorf and Heinrich Heine University, Düsseldorf, Germany

² Department of Cardiology, Pneumology, and Vascular Medicine, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany

³ Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany

⁴ Institute of Pharmacology, University Hospital Düsseldorf, Düsseldorf, Germany

⁵ Institute of Cardiovascular Physiology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

⁶ Department of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany

⁷ Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA 24060, USA

| | |
|--------------|---|
| I/R | Ischemia/reperfusion |
| KO | Knock-out |
| LC-MS/MS | Liquid chromatography with tandem mass spectrometry |
| LTCC | L-type calcium channel |
| LVH | Left-ventricular hypertrophy |
| MeOH | Methanol |
| Mfsd2b | Major facilitator superfamily domain containing 2b |
| MLC2 | Myosin light chain 2 |
| MRM | Multiple reaction monitoring |
| MYBPC3 | Myosin-binding protein C, cardiac-type |
| NCX | Sodium-calcium exchanger |
| Pak1 | P21 activated kinase-1 |
| PKC α | Protein kinase C alpha |
| PLN | Phospholamban |
| PP2A | Protein Phosphatase 2A |
| PVDF | Polyvinylidene difluoride |
| qPCR | Quantitative Polymerase Chain Reaction |
| RBC | Red blood cells |
| RyR2 | Ryanodine receptor |
| SEM | Standard error of the mean |
| SERCA2a | Sarcoplasmic reticulum calcium ATPase |
| SMAPs | Small molecule activators of PP2A |
| Spns2 | Spinster-2 |
| S1P | Sphingosine-1-Phosphate |
| S1PR1-5 | Sphingosine-1-Phosphate Receptors 1–5 |
| TnI/T | Troponin I/T |

Introduction

Hypertension represents a major risk factor for the development of cardiovascular diseases [5] affecting more than 1 billion people worldwide [40, 41]. In hypertensive patients, the heart is subjected to chronic pressure overload and adapts by left-ventricular hypertrophy (LVH) [18, 34], with a high prevalence of LVH in hypertensive populations [3]. Accompanied by overactivation of the renin–angiotensin–aldosterone axis, sustained hypertension leads to heart failure [5, 17, 57] and, subsequently, increased mortality [34]. Cardiomyocyte calcium (Ca^{2+}) overload is a major factor predisposing the myocardium to heart failure [49]. Physiologically, myocardial Ca^{2+} homeostasis controls the balance between relaxation and contraction in the cardiac systole and diastole [7, 13]. This homeostasis is controlled by voltage-gated L-type calcium channels (LTCC), the sodium-calcium exchanger (NCX) and the SR calcium ATPase (SERCA2a) [8].

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid with numerous effects on the cardiovascular system, where it acts both as an intracellular second messenger and extracellular ligand to five G-protein coupled receptors

(S1PR1–5) [24, 32, 54]. In the heart, S1P modulates contractility [20, 35], Na^{2+} and Ca^{2+} homeostasis [25], protects against ischemia/ reperfusion (I/R) injury [10, 51, 60], improves cardiac remodeling after I/R [45], contributes to preconditioning [19, 24, 25, 61] and participates in the pathophysiology of hypertrophy and heart failure [47]. Plasma S1P levels in humans have been linked to hypertension [21], heart failure [63], myocardial infarction [50], and ischemic heart diseases [44].

Plasma S1P is mainly supplied by endothelial cells (EC), red blood cells (RBC), and platelets through two designated S1P transporters: Spinster-2 (Spns2) in EC [11] and Major facilitator superfamily domain containing 2 b (Mfsd2b) in RBC and platelets, respectively [62]. We have recently shown that Mfsd2b-dependent release of S1P from platelets limits infarct size during murine myocardial infarction, and that plasma S1P levels after myocardial infarction are associated with reduced cardiovascular mortality in ST-elevation myocardial infarction patients [42]. In the present study, we asked the question if Mfsd2b is expressed in the adult heart and, if so, whether it plays a functional role in an angiotensin II (AngII) model of heart failure.

Methods

Mouse models

All mouse experiments were approved by the local animal ethics committee (LANUV Recklinghausen, Germany) under file number: 81-02.04.2021.A012 and performed according to the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Council of Europe Treaty Series No. 123). Mouse care was executed according to the institutional guidelines. Mice were housed within the central animal research facility of the Heinrich Heine University Düsseldorf on a 12/12 h light/dark cycle with ad libitum drinking water and a standard rodent diet. Experiments using mice were planned according to the ARRIVE recommendations [26]. Mfsd2b^{-/-} mice were purchased from the MMRRC at UC Davis. All experiments were performed in 22 week old male mice.

Hypertension-induced cardiac remodeling

Global Mfsd2b^{-/-} and Mfsd2b^{+/+} mice were subjected to 4-weeks AngII (1000 ng·kg⁻¹·min⁻¹) treatment using subcutaneous osmotic minipumps (model 2004, Alzet, Cupertino, CA). Before implantation, mice were anesthetized with isoflurane (2–2.5% initiation, 1.5–2% steady state). This induced reliably hypertension with consecutive cardiac remodeling and left-ventricular deterioration as previously

shown [56]. Following the 4-week treatment and after the echocardiographic assessment of left-ventricular functional parameters, mice were sacrificed, and hearts collected for further analysis.

Echocardiographic assessment of cardiac function

Cardiac echocardiography was performed before and after AngII treatment as described [9, 43, 45]. Mice were anesthetized using isoflurane anesthesia (2–2.5% initiation, 1.5–2% steady state) with constant cardiocirculatory rate (heart rate: 400–600 bpm, breathing rate: ~100/min). The left-ventricular systole and diastole were recorded using a high-resolution ultrasound system (18–38 MHz; Vevo 3100, Visual Sonics Inc., Toronto, Canada). Functional parameters, i.e., left-ventricular volume at the end of systole or diastole, stroke volume, cardiac output, and ejection fraction, were calculated in B-mode by identification of maximal and minimal cross-sectional area using the manufacturer's software Vevo Lab 5.6.1 (Visual Sonics Inc., Toronto, Canada).

Liquid chromatography with tandem mass spectrometry (LC-MS/MS)

Plasma and tissue samples were extracted by precipitation in methanol. Internal standard (1 μ M C17 S1P in MeOH, 10 μ l) was added to weighted heart tissue, homogenized in MeOH (1 ml), and precipitated at -80°C overnight. Tissue sample supernatants were concentrated in a vacuum rotator (60 $^{\circ}\text{C}$, 1 h), the residue dissolved in MeOH (100 μ l) and transferred into mass spectrometry vials. Chromatographic separation was performed on an LCMS-8050 triple-quadrupole mass spectrometer (Shimadzu Duisburg, Germany) interfaced with a Dual Ion Source and a Nexera X3 Front-End-System (Shimadzu Duisburg, Germany). High-performance liquid chromatography was performed with a 60 \times 2 mm Multo-High-C18 RP column with 3 μ m particle size at 40 $^{\circ}\text{C}$ (CS Chromatographie Service, Langerwehe, Germany). Mobile phases consisted of [A] = MeOH and [B] = 1% (v/v) aq. HCO₂H. The following LC gradient settings were used: Nebulizer: 3 L/min, Interface Temperature 300 $^{\circ}\text{C}$, Desolvation Temperature 526 $^{\circ}\text{C}$, Heat Block Temperature 400 $^{\circ}\text{C}$ and Drying Gas Flow 10 L/min. The flow rate was 400 μ l/min, and injection volume 10 μ l (Supplemental Table 1). Standard curves were generated by measuring increasing amounts (10 fmol to 50 pmol) of S1P and internal standard (C17 S1P, 0.1 μ M final conc. in MeOH). The linearity of the standard curves and correlation coefficients were obtained by linear regression analysis. Data were collected using multiple reaction monitoring (MRM). The mass transitions for analysis in multiple reaction monitoring (MRM) modes were $m/z = 380/264$ and $380/82$ for S1P and $m/z = 366/250$ for

C17 S1P. Data analysis was performed with LabSolutions 5.114 (Shimadzu, Kyoto, Japan).

Western blotting

Isolated ACMs were preincubated with sphingosine (1 μ M) for 30 min and stimulated with isoprenaline (1 μ M) for 5 min. Cells were lysed in RIPA buffer (in mM: 10 Tris pH 8.0, 0.5 EGTA, 0.5% Triton™ X-100, 0.1% desoxycholic acid, 0.1% SDS, 140 NaCl) containing protease inhibitors and phosphatase inhibitors (HALT™, Thermo Scientific). Protein concentration was determined by BCA assay (Pierce) and 50 μ g of lysate mixed with 4 \times Laemmli sample buffer without boiling. Samples were separated on a 6% gel and transferred to a PVDF membrane (400 mA, 4 h, on ice). The membranes were probed for p-LTCC-Ser1981 (PA5-64748, 1:1000) and Calsequestrin/CASQ (26,625, 1:1000) both from Thermo Fisher, Germany. Heart tissue was snap-frozen and stored at -80°C . Lysates were prepared Heart by mechanical disruption (Ultra-Turrax® T10 Basic, Ika®) in modified RIPA buffer containing protease and phosphatase inhibitors before adding Laemmli sample buffer. To preserve phospholamban (PLN) oligomers, samples were only heated to 40 $^{\circ}\text{C}$. Protein concentrations were determined by bicinchoninic acid assay (Pierce® BCA Assay Kit, Thermo Scientific) and equal amounts of total protein were loaded to the gels. Proteins were separated by SDS-PAGE with 15% polyacrylamide gels (6% for RyR2) and transferred to polyvinylidene difluoride (PVDF) membrane (Immobilon-P, 0.45 μ m pore size, Millipore). For titin analysis frozen heart tissue was solubilized in modified Laemmli buffer and proteins were separated on agarose-strengthened 2.1% PAGE. To determine titin isoform composition proteins were visualized by imperial protein staining solution (Thermo Scientific). To analyze titin phosphorylation proteins were then transferred to a PVDF -membrane and processed as previously described [28]. Membranes were blocked with 0.5% milk/TBS-T (in mM: 10 Tris, 150 NaCl, 0.1% Tween 20, and pH 7.6, SNAP i.d.® 2.0, Millipore) and incubated with primary antibodies overnight at 4 $^{\circ}\text{C}$ in 5% milk/TBS-T. Reactive bands were visualized by enhanced chemiluminescence using horse-radish peroxidase-coupled secondary antibodies (abcam) and Immobilon® Forte Western HRP substrate (Millipore). Signals were digitally quantified using a CCD camera system and associated software (ChemStudio, VisionWorks, AnalytikJena). The following antibodies were used for detection: Ryanodine receptor 2 (RyR2) (Thermo Fisher Scientific, PA5-87,416, 1:5000 dilution), pRyR2(S2814) (Badrilla, S2814, A010-31, 1,5000), PLN (Badrilla, clone A1, 1:5000), phospho-PLN(S16) (Badrilla, S16, 1:5000), cardiac Troponin I (TnI) (Cell Signaling Technology®, #4002, 1:5000), phospho-TnI (S23/24) (Cell Signaling Technology®, #4004, 1:5000), Troponin T (TnT)

(S23/24) (Cell Signaling Technology®, #5593, 1:5000), Calsequestrin (PA1–913, Thermo Fisher Scientific, 1:5000 dilution), cardiac-type myosin-binding protein C (MYBPC3) (Thermo Fisher Scientific, #703574, 1:5000), myosin light chain 2 (MLC2) (Affbiotech, 1:5000), phospho-MLC2 (S15) (Affbiotech, 1:5000), α -PKC α (Abcam, ab32376), α -phospho-PKC α T497 (Abcam, ab76016). Titin domain phosphorylation was tested using custom made (Eurogentec) phosphosite directed antibodies to pSer4010, pSer4099, pSer4062, and pSer11878 (human cardiac titin; UniProtKB: Q8WZ42) and control antibodies recognizing the phosphorylated and unphosphorylated PEVK-fragment (pan-Titin). Chemiluminescent detection using horse-radish peroxidase-coupled secondary antibodies (Sigma) and Immobilon Forte HRP substrate (Millipore) was used to visualize signals. Quantitative analysis of unsaturated signals in the linear range of detection was performed using Fusion SOLO imaging system (Vilber Lourmat) and associated software (Multi Gauge V3.2 or ChemStudio, AnalytikJena). Differences in phosphorylation levels, the ratio of signal intensities phospho:pan was calculated for each sample and with each set of phosphosite-directed antibodies.

Blood pressure measurements by tail-cuff system

Blood pressure was measured noninvasively using a computerized tail-cuff system (Hatteras Inc.). Mice were subjected to several measurements before pump implantation to adapt to the device. After baseline measurements before pump implantation, blood pressure was measured in a 3-day interval for 25 days.

Measurements of cardiomyocyte Ca²⁺ cycling and sarcomere length

Ca²⁺-cycling analyses were performed in isolated cardiomyocytes from *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} mice. For isolation, the murine hearts were digested by 6 min of retrograde perfusion with collagenase type I (Worthington Biochemical Corp., Lakewood, NJ, USA). The further procedures (i.e., ACM isolation, recalcification, cell loading with Fura-2 AM, and consecutive measurements) were performed similarly to those previously described [29, 52]. Briefly, after Fura-2 loading, the myocytes received superfusion with a 37 °C buffer containing (in mM) 137 NaCl, 5.4 KCl, 1.2 CaCl₂, 1 MgCl₂, 10 HEPES, 5.5 glucose, the pH of which was corrected to 7.4. ACM were then paced at 0.5 Hz in an electric field. Ca²⁺ transients were recorded at 340 and 380 nm excitation wavelengths using a dual-excitation fluorescence imaging/ contractility recording system (HyperSwitch Myocyte System, IonOptix Corp., Milton, MA, USA). Perfusion buffer containing 10–7 M isoprenaline (iso) was applied to the bath with Fura-2-loaded myocytes for β -adrenergic

stimulation. Isoprenaline-stimulated cells were further measured upon exposure to the LTCC inhibitor verapamil (10⁻⁵ M). Data analysis was performed using IonWizard software (Version 6.4, IonOptix Corp.). Ratiometric data obtained at 340/380 nm in 10 independent Ca²⁺ transient measurements per myocyte were averaged. One heart composed readings from 10 corresponding myocytes, and 10 hearts were analyzed per group. Sarcomere contraction and relaxation variables were measured in paced cardiomyocytes via video detection (MyoCam-S™, IonOptix). Data were analyzed using IonWizard software (Version 6.4).

Preparation of skinned cardiac fibers and mechanical measurements

Papillary muscles were prepared from the left ventricles of *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} mice and stored at –20 °C in 50% glycerol: 50% low ionic strength buffer (75 mM potassium chloride, 10 mM Tris–HCl, 2 mM Mg-chloride, 2 mM EGTA, 100 mM protease inhibitor cocktail, 50 mM phosphatase inhibitor cocktail, pH 7.1) until use. For tension measurements, papillary muscles were skinned overnight in relaxing solution (7.8 mM ATP, 20 mM creatine phosphate, 20 mM imidazole, 4 mM EGTA, 12 mM Mg-propionate, 97.6 mM K-propionate, pH 7.0, 30 mM 2,3-butanedione monoxime (BDM), 1 mM dithiothreitol (DTT), 100 mM protease inhibitor cocktail, 50 mM phosphatase inhibitor cocktail) supplemented with 1% wt/vol TritonX-100 on ice. The skinned tissues were then extensively washed in relaxing solution without TritonX-100, and small fiber bundles with diameters of 200–350 μ m and a length of 1.0–2.0 mm were dissected. Force measurements were performed with a muscle mechanics workstation (Myotronic, Heidelberg, Germany) at room temperature [30]. Skinned left-ventricular fiber bundles were bathed in relaxing solution (7.8 mM ATP, 20 mM creatine phosphate, 20 mM imidazole, 4 mM EGTA, 12 mM Mg-propionate, 97.6 mM K-propionate, pH 7.0, 30 mM BDM, 1 mM DTT, 100 mM protease inhibitor cocktail, 50 mM phosphatase inhibitor cocktail) and mounted to the motor arm and force transducer between stainless steel clips. Passive tension was determined by stepwise stretching the mounted fibers to a maximum of 130% of slack length. To measure Ca²⁺-sensitivity of force development, skinned fiber bundles were mounted in relaxing solution without BDM and were pre-stretched by 20% of their slack length. Force-pCa relations were determined by sequentially increasing Ca²⁺-concentration to pCa 4.5. Averaged data (mean \pm SEM) on relative-force vs. pCa diagrams were fitted by using the Hill equation. Force data were related to cross-sectional area determined from the diameter of the specimens (by assuming a cylindrical shape and circular cross-sectional area).

Quantitative PCR

RNA was isolated from heart tissue and ACM using the innuPREP RNA Mini Kit (Analytik Jena, Jena, Germany) according to the manufacturer instructions. Synthesis of cDNA (200 ng) was performed by using the Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, USA). Gene expression was quantified by quantitative PCR (qPCR) via SYBR Green (Bio-Rad Laboratories, Hercules, USA). Primer sequences are listed in Supplemental Table 2. As an internal control for normalization GAPDH was used.

Histology

Heart tissue was fixed in 4% paraformaldehyde overnight and embedded in paraffin. Serial transverse sections of 5 μ m were stained with Sirius red.

PP2A assay

PP2A activity in heart tissue of Mfsd2b^{+/+} and Mfsd2b^{-/-} mice was assessed using the PP2A Immunoprecipitation Phosphatase Assay Kit (# 17-313 from Merck, Darmstadt, Germany) with minor modifications to the manual's procedure To immunoprecipitate PP2A, heart tissue lysates containing 1000 μ g protein or murine ACM containing 500 μ g protein were incubated in a total volume of 500 μ l pNPP Ser/Thr Assay buffer with 8 μ g of anti-PP2A-C subunit antibody (clone 1D6, #05-421) and 25 μ l of protein A agarose slurry for 18 h at 4 °C with constant head over head rotation of 10 rpm. Phosphatase activity was determined via the amount of free inorganic phosphate released by the enzymatic conversion of threonine phosphopeptide. The generated orthophosphate reacts with the malachite green detection solution and is quantified by measuring absorption at 650 nm in a microplate reader (BMG LABTECH GmbH, Offenburg, Germany) after 35 min of development. PP2A activity was also measured in ACM cultured in M199 media (containing creatine 5 mM; carnitine 2 mM; taurine 5 mM; 1 \times Insulin-Transferrin-Selen/Anti-Anti/glutamine; 5% FCS, 10 μ M blebbistatin) on laminin (10 μ g/mL) stimulated for 30 min as indicated and harvested in lysis buffer with protease inhibitor on ice. For LC-MS/MS measurements, 150,000 ACM were transferred to a laminin (10 μ g/mL) coated cell culture plate and incubated with sphingosine (1 μ M) or vehicle (ethanol) control for 30 min. After washing with ice-cold HBSS the final pellet was taken up in methanol for LC-MS/MS.

Statistical analysis

The presented results are displayed as mean \pm standard error of the mean (SEM). Unless otherwise specified, we used an unpaired Student's *t* test (for normally distributed data) or a Mann–Whitney-*U*-Test (for non-normally distributed data) to test whether the two data groups were significantly different. Normal distribution was tested through the D'Agostino-Pearson test. For repeated measurements, data were analyzed by one-way and two-way analysis of variance (ANOVA), as appropriate, followed by Bonferroni's, Sidak's or Holm-Šidák's multiple comparisons test post hoc tests. $p < 0.05$ was considered statistically significant. Statistical analysis was done using GraphPad Prism 9 for Windows (GraphPad Software, San Diego, CA, USA).

Results

Mfsd2b is expressed and functionally active in the murine and human heart

We observed that Mfsd2b is expressed in the adult C57BL/6 mouse heart and in isolated adult mouse cardiomyocytes by real-time qPCR (Suppl. Fig. 1A). S1P concentrations were 1.6-fold higher in Mfsd2b^{-/-} hearts compared to Mfsd2b^{+/+} hearts as determined by LC/MS–MS suggesting functional activity (Mfsd2b^{+/+}: 1.19 \pm 0.13 vs. Mfsd2b^{-/-}: 1.91 \pm 0.16 pmol/mg heart tissue; $p = 0.0022$). Mfsd2b was also expressed in human hearts (Suppl. Fig. 1B).

Mfsd2b^{-/-} mice are protected against AngII-induced cardiac remodeling

Heart weight and left-ventricular function were indistinguishable between Mfsd2b^{-/-} and Mfsd2b^{+/+} mice under basal conditions. However, AngII infusion for four weeks revealed clear differences in the cardiac response to pressure overload: Mfsd2b^{+/+} mice demonstrated intra-individual deterioration of left-ventricular function compared to baseline, whereas Mfsd2b^{-/-} mice were largely unaffected with preserved left-ventricular function. This was most evident in stroke volume (Mfsd2b^{+/+}: 39 \pm 1.8 at baseline vs. 22.9 \pm 1.9 μ l after AngII, $p < 0.0001$ compared to Mfsd2b^{-/-}: 37.5 \pm 2 at baseline vs. 31.7 \pm 1.9 μ l after AngII, $p = 0.0760$, Fig. 1H), ejection fraction (Mfsd2b^{+/+}: 50.6 \pm 2 at baseline vs. 33.2 \pm 3.3% after AngII, $p < 0.0001$ compared to Mfsd2b^{-/-}: 45.8 \pm 2.2 at baseline vs. 39.5 \pm 2.1% after AngII, $p = 0.1404$, Fig. 1I) and cardiac output (Mfsd2b^{+/+}: 16.5 \pm 0.7 at baseline vs. 9.9 \pm 0.7 ml/min after AngII, $p < 0.0001$ compared to Mfsd2b^{-/-}: 15.6 \pm 0.9 (SEM) at baseline vs. 13.8 \pm 0.7 ml/min after AngII, $p = 0.1885$, Fig. 1J). The end-systolic




Fig. 1 Four weeks of AngII infusion deteriorate the left-ventricular function of *Mfsd2b*^{+/+} but not *Mfsd2b*^{-/-} mice. *Mfsd2b*^{-/-} leads to cardiac S1P and Sphingosine accumulation. **A** Heart weights of *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} with and without AngII treatment. $n_{WT}=20$, $n_{WT+AngII}=10$, $n_{KO}=21$, $n_{KO+AngII}=9$. Data is presented as mean \pm SEM. Statistical significance was analyzed by two-way ANOVA followed by Sidak's multiple comparison test. *p* values are as indicated above the compared data sets. **B** Body weights of *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} before and after AngII treatment. $n_{WT}=20$, $n_{WT+AngII}=10$, $n_{KO}=21$, $n_{KO+AngII}=9$. Data is presented as mean \pm SEM. Statistical significance was analyzed by two-way ANOVA followed by Sidak's multiple comparison test. *p* values are as indicated above the compared data sets. **C** Corrected left-ventricular mass after AngII treatment measured by B-mode echocardiography. $n_{WT}=15$, $n_{WT+AngII}=15$, $n_{KO}=14$, $n_{KO+AngII}=16$. Data is presented as mean \pm SEM. Statistical significance was assessed by RM two-way ANOVA followed by Sidak's multiple comparison test. *p* values are as indicated above the compared data sets. **D** S1P and **E** Sphingosine levels in heart tissue from *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} mice before and after AngII treatment as measured by LC-MS/MS. $n_{WT}=12$, $n_{WT+AngII}=9$, $n_{KO}=16$, $n_{KO+AngII}=9$. Data is presented as mean \pm SEM. Statistical significance was assessed by RM two-way ANOVA followed by Tukey's multiple comparisons test. *p* values are as indicated above the compared data sets. **F** S1P levels in plasma from *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} mice before and after AngII treatment as measured by LC-MS/MS. $n_{WT}=12$, $n_{WT+AngII}=9$, $n_{KO}=16$, $n_{KO+AngII}=9$. Data is presented as mean \pm SEM. Statistical significance was assessed by RM two-way ANOVA followed by Tukey's multiple comparisons test. *p* values are as indicated above the compared data sets. **G** Heart rate, **H** Stroke volume, **I** left-ventricular ejection fraction, **J** cardiac output, **K** end-systolic volume, **L** end-diastolic volume, **M** anterior and **N** posterior wall thickness before and after 4-weeks of AngII treatment in the same mice. **G–N** $n_{WT}=15$, $n_{WT+AngII}=15$, $n_{KO}=14$, $n_{KO+AngII}=16$. Data is presented as mean \pm SEM. Statistical significance was assessed by RM two-way ANOVA followed by Sidak's multiple comparison test. *p* values are as indicated above the compared data sets

volume was also increased in *Mfsd2b*^{+/+} (39 ± 2.9 at baseline vs. 54.5 ± 6.1 μ l after AngII, $p=0.0385$), whereas it was unchanged in *Mfsd2b*^{-/-} (44.8 ± 3.8 at baseline vs. 50 ± 4.6 μ l after AngII, $p=0.6767$; Fig. 1K). The end-diastolic volumes and heart rates were unchanged between groups (Fig. 1G and L). Following AngII treatment, *Mfsd2b*^{-/-} showed a higher degree of hypertrophy, especially of the left-ventricular posterior wall (0.85 ± 0.05 at baseline vs. 1.2 ± 0.1 μ l after AngII, $p=0.0074$), which was not visible in *Mfsd2b*^{+/+} mice (0.87 ± 0.06 at baseline vs. 1.07 ± 0.07 μ l after AngII, $p=0.1517$, Fig. 1N). Blood pressure was similarly increased in both genotypes (Suppl. Fig. 2). Despite preserved left-ventricular function in *Mfsd2b*^{-/-} mice, the degree of hypertrophy after AngII was similar as measured by echocardiography, heart weight, fibrosis and embryonic gene expression (Fig. 1A–C and Suppl. Fig. 3). AngII treatment led to elevations in S1P and sphingosine levels in hearts of both strains (Fig. 1D, E) and resulted in higher plasma S1P (Fig. 1F) in both genotypes in line with the literature [36, 53].

Mfsd2b^{-/-} cardiomyocytes display reduced Ca²⁺ mobilization and cycling but preserved contractility after isoprenaline

We assessed intracellular Ca²⁺ dynamics in ACM of *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} by measuring amplitude and speed of enrichment as well as speed of return to baseline (Fig. 2A and B). All parameters were similar under basal conditions between the genotypes but stimulation with isoprenaline revealed a clear $\sim 50\%$ reduction in Ca²⁺ amplitude, speed of enrichment and return to baseline, respectively, in ACM from *Mfsd2b*^{-/-} compared to *Mfsd2b*^{+/+} mice (Fig. 2C). Sarcomere contraction and relaxation patterns were similar under isoprenaline-stimulated conditions in both genotypes (Fig. 2D) as measured by contraction amplitude and contraction/relaxation speed. Of note, the amplitude of contraction was significantly higher in *Mfsd2b*^{-/-} cardiomyocytes under basal conditions (Fig. 2D). Comparisons between the two genotypes in non-parametric tests were also significant in speed of contraction and relaxation, respectively. This suggests that several myofilament proteins are relatively more sensitive to calcium-dependent activation resulting in similar contractility despite lower calcium cycling.

Analysis of expression and phosphorylation levels of the essential proteins responsible for Ca²⁺ homeostasis in *Mfsd2b*^{-/-} and *Mfsd2b*^{+/+} ACM revealed similar levels of p(S16)-PLN (Fig. 3A), p(S2814)-Ryr2 (Fig. 3B), and p(S19)-MLC2 (Fig. 3E) and no differences in the phosphorylation of the calcium-sensitive contractile protein TnI as determined by p(S23/24)-TnI levels (Fig. 3D). The total levels of RyR2, PLN, SERCA2a, MLC2, TNI, TNT, and MyBPC were also comparable between ACM of both genotypes (Fig. 3).

Verapamil abolishes the differences in calcium cycling between *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-}

S1P has been shown to affect cardiomyocyte Ca²⁺ homeostasis and inhibit LTCC in rat ventricular myocytes [6, 25]. This prompted us to examine whether enhanced LTCC activity through S1P accumulation due to lack of *Mfsd2b*-mediated S1P export was responsible for the effects. Indeed, the marked differences in Ca²⁺ transients after isoprenaline stimulation between *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} were abolished in the presence of the LTCC blocker verapamil (Fig. 4A) and contractility suppressed to a similar extent (Fig. 4B).

Increased PP2A activity in *Mfsd2b*^{-/-} whole hearts and cardiomyocytes

S1P inhibition of the L-type calcium current has been suggested to occur through PP2A signaling [6] but the




Fig. 2 Impaired intracellular Ca^{2+} cycling but preserved sarcomere contractility of $\text{Mfsd2b}^{-/-}$ ACM upon stimulation with isoprenaline. **A** Schematic representation of Ca^{2+} transients and **B** variables of sarcomere length. **B** Ca^{2+} transient amplitude and kinetics of paced $\text{Mfsd2b}^{+/+}$ and $\text{Mfsd2b}^{-/-}$ ACM at baseline and upon stimulation with isoprenaline (10^{-7} M). **C** Amplitude of contraction and kinet-

ics of sarcomere shortening in $\text{Mfsd2b}^{+/+}$ and $\text{Mfsd2b}^{-/-}$ ACM at baseline and upon stimulation with isoprenaline (10^{-7} M). $n_{\text{WT}}=10$, $n_{\text{KO}}=10$. Statistical significance was assessed by two-way ANOVA followed by Tukey's multiple comparisons test. p values are as indicated above the compared data sets

mechanism has remained unexplored. PP2A was shown to regulate calcium transients by inhibiting protein kinase A-dependent LTCC activation by dephosphorylation [31]. Sphingoid bases and analogs such as sphingosine and C2 ceramide have been shown to disrupt membrane trafficking of glucose and amino acid transporters by activating PP2A [14, 22, 27], and that intracellular S1P directly binds to and activates the catalytic subunit of PP2A [58]. Thus, we

measured PP2A activity in $\text{Mfsd2b}^{-/-}$ and $\text{Mfsd2b}^{+/+}$ hearts and observed it to be 1.2-fold higher in $\text{Mfsd2b}^{-/-}$ compared to $\text{Mfsd2b}^{+/+}$ ($p=0.0207$, Fig. 4C). We then isolated ACM and showed that increasing intracellular S1P by supplementing sphingosine resulted in an eightfold increase of ACM S1P levels (0.13 ± 0.02 at baseline vs. 1.07 ± 0.18 pmol/mg.; $p=0.0078$) and to a ~20% higher PP2A activity (338.4 ± 35.5 at baseline vs. 410.5 ± 34.1 a.u.; $p=0.0322$)





Fig. 3 Similar phosphorylation levels of RyR2, PLN, MLC, SERCA2a, and TnI in heart tissue from Mfsd2b^{+/+} and Mfsd2b^{-/-} mice. WB analysis of phospho- and total-RyR2, PLN, MLC, SERCA2a,

and TnI in the two genotypes. $n_{WT}=7$, $n_{KO}=9$. Data is presented as mean \pm SEM. An unpaired Student *t* test was used for statistical analysis. *p* values are as indicated above the compared data sets

(Fig. 4D). This suggests that accumulation of S1P in cardiomyocytes leads to PP2A activation. We then stimulated ACM with isoprenaline after raising intracellular S1P

(Fig. 4E) and measured Ser1981 phosphorylation in LTCC, a target site for PP2A [4, 16], as a proxy for LTCC activity. Five minutes of isoprenaline lead to a ~20-fold increase in

Fig. 4 Reduced intracellular Ca^{2+} cycling upon stimulation with isoprenaline in $\text{Mfsd2b}^{-/-}$ ACM is abolished by verapamil. Effects of Mfsd2b and S1P on PP2A and LTCC activity. **A** The LTCC inhibitor verapamil (vera, 10^{-5} M) abolished the reduced Ca^{2+} cycling of isoprenaline-stimulated $\text{Mfsd2b}^{-/-}$ ACM. **B** Verapamil (vera, 10^{-5} M) effects on sarcomere contraction and relaxation in isoprenaline-treated ACM. $n_{\text{WT}}=8$, $n_{\text{KO}}=8$. Data is presented as mean \pm SEM. Two-way ANOVA followed by Tukey's multiple comparison test were used for statistical analysis. p values are as indicated above the compared data sets. **C** PP2A activity from cardiac tissue from $\text{Mfsd2b}^{+/+}$ and $\text{Mfsd2b}^{-/-}$ mice. $n_{\text{WT}}=8$, $n_{\text{KO}}=8$. Data is presented as mean \pm SEM. An unpaired Student's t test was used for statistical analysis. p -value is as indicated above the compared data sets. **D** PP2A activity in C57BL/6 ACM before and after S1P loading using sphingosine. $n=11$ for both groups. A Wilcoxon test was used for statistical analysis. p -value is as indicated above the compared data sets. **E** S1P levels in C57BL/6 ACM before and after S1P loading using sphingosine as measured by LC-MS/MS. $n=8$ for both groups. A Wilcoxon test was used for statistical analysis. p -value is as indicated above the compared data sets. **F** Representative western blots and densitometric analysis of the levels of p(Ser1981)-LTCC and total LTCC in ACM from C57BL/6 at baseline and after stimulation with Isoprenaline (iso) (1 μM), Sphingosine (Sph) (1 μM) or both substances (Iso + Sph). $n_{\text{Control}}=5$, $n_{\text{Sph}}=5$, $n_{\text{Iso}}=5$, $n_{\text{Iso+Sph}}=5$. Statistical significance was analyzed by one-way ANOVA with Holm-Šidák's multiple comparisons test. p values are as indicated above the compared data sets



Ser1981-LTCC phosphorylation that was reduced by ~25% in S1P-loaded cells (Fig. 4F). This is a clear indication that raising intracellular S1P inhibits LTCC phosphorylation and hence activity.

Cardiac fibers from *Mfsd2b*^{-/-} mice show reduced passive tension generation upon stretch but preserved contractile function

It is assumed that an increase in cardiomyocyte passive stiffness and calcium sensitivity can partially compensate for functional limitations caused by disturbed cellular Ca²⁺ handling [12]. We therefore tested passive tension using permeabilized fiber bundles from papillary muscles of *Mfsd2b*^{+/+} and *Mfsd2b*^{-/-} and detected a 40–45% reduction in the force-extension curve of fibers from *Mfsd2b*^{-/-} mice, when stretched to > 118% of slack length (Fig. 5A). Prompted by this finding we performed Western blot analyses using left-ventricular tissue samples from both groups and tested for phosphorylation (indicative for activation) of the kinases PKC α and ERK1/2 and of the sarcomeric target protein titin, a major determinant of cardiomyocyte passive stiffness. Our analyses showed no statistically significant difference in the relative phosphorylation of PKC α and ERK1/2, and of titin phosphorylation at S12022 and S11878 in the PEVK region of the protein, and at S4010 and S4099 in the N2B region (Fig. 5B, C).

Despite the clear reduction in *Mfsd2b*^{-/-} fibers' passive tension upon stretch, maximal Ca²⁺-induced force production was similar (37.7 ± 3.2 mN/mm² in *Mfsd2b*^{+/+} and 46.7 ± 4.4 mN/mm² in *Mfsd2b*^{-/-}; $p=0.1205$) as were kinetics of force development and force decay (0.29 ± 0.04 mN/mm²*s and 1.78 ± 0.23 mN/mm²*s in *Mfsd2b*^{+/+} vs. 0.47 ± 0.09 mN/mm²*s and 2.39 ± 0.30 mN/mm²*s in *Mfsd2b*^{-/-}; Fig. 5D). Fibers from both genotypes displayed also similar Ca²⁺-sensitivity of force development with log_{EC50} of 5.648 in *Mfsd2b*^{+/+} and 5.649 in *Mfsd2b*^{-/-} mice (Fig. 5E).

Discussion

The current study presents the following novel findings: (1) The S1P exporter *Mfsd2b*, previously characterized only in RBC, is expressed and functional in the heart where it regulates cardiomyocyte S1P export; (2) Lack of *Mfsd2b* in cardiomyocytes and the concomitant increase in intracellular S1P suppress intracellular calcium cycling; (3) This is mediated by lower LTCC activity as measured by reduced Ser1981 phosphorylation due to S1P-mediated activation of its negative regulator PP2A; (4) This mechanism protects the heart against AngII-mediated cardiac remodeling.

S1P has multiple effects on cardiomyocyte function, ion currents and contractility but almost all of them are exerted through S1P receptor signaling [20, 24, 35, 61]. In contrast, we have identified a novel function of intracellular S1P in cardiomyocytes that became apparent when *Mfsd2b* was missing. Although intracellular effects of S1P as a second messenger have long been known [55] and were described even before the first S1P receptors were cloned, only few targets of intracellular S1P have been identified and none in relation to calcium. In fact, acute release of caged S1P by photolysis was shown to mobilize intracellular calcium from thapsigargin-sensitive stores independently of S1P receptor signaling some 15 years ago [39]. In contrast, chronically high intracellular S1P as in *Mfsd2b* deficiency attenuated isoprenaline-induced calcium mobilization in our hands but did not affect cardiomyocyte contractility. While the former suggests that calcium influx and/or release were affected, the latter implies that the calcium sensitivity of the contractile apparatus must have increased in a compensatory manner. In line with this, we have previously demonstrated higher calcium sensitivity of the contractile apparatus in cardiomyocytes after deletion of the S1P receptor 1 despite lower systolic and diastolic calcium [25]. In fact, extracellular and intracellular S1P signaling are interconnected as S1P receptor 1 has been shown to mobilize calcium by activating intracellular S1P production [38], hence the high intracellular S1P present in *Mfsd2b*-deficient cardiomyocytes may phenocopy S1P receptor 1 signaling. However, we did not find any changes in any proteins responsible for Ca²⁺ homeostasis and their phosphorylation in ACM. Furthermore, Ca²⁺ sensitivity of force development and phosphorylation of cardiac TnI were unchanged in permeabilized papillary muscle fibers from *Mfsd2b*^{-/-} mice. We hypothesized that increased passive stiffness of the contractile apparatus could contribute to the observed increased amplitude of contraction but found that papillary muscle fibers from *Mfsd2b*^{-/-} mice actually showed lower passive tension values in response to stretch. This reduction in passive tension was not explained by altered phosphorylation of titin tested at four different sites of phosphorylation in the elastic N2Bus and PEVK region, which have previously been described to modulate cardiomyocyte stiffness and affect myocardial function [33]. However, our results do not exclude the possibility that the reduction in passive tension is due to other post-translational modifications of titin or changes in the extracellular matrix (ECM). Several other proteins, such as the endothelial integrin-linked kinase and the cardiac fibroblast glycogen synthase kinase-3 α , appear to be involved in cardiac function and its remodeling in diseases [46, 59]. Future studies should explore the compensatory mechanisms preserving contractility in *Mfsd2b*^{-/-} mice.

The pathophysiological consequence of our findings in a setting of hypertension-induced cardiac strain may




Fig. 5 Reduced passive tension but preserved Ca²⁺-dependent force production in cardiac tissue from Mfsd2b^{-/-} mice. **A** Individual data points comparing passive tension values of permeabilized fiber bundles from papillary muscle after stepwise stretching to 110, 120 or 130% of resting fiber length. Lines represent polynomial fit to the data. Schematic stretch protocol is shown below the graph. **B** Western blot analyses of left-ventricular tissue from Mfsd2b^{+/+} and Mfsd2b^{-/-} hearts using phospho-specific antibodies to PKCα T497 and ERK 1/2 T202/Y204. Signals were normalized to total PKCα or ERK 1/2. Representative Western blot images are shown below the bar graphs. **C** Western blot analyses using phospho-specific antibodies to titin phosphorylated at S12022, S11878, S4010 and S4099. Signals were

normalized to total titin. Bar graphs show mean ± SEM from $n_{WT}=6$ and $n_{KO}=7$ mice. **D** Maximum Ca²⁺-induced force development at pCa 4.5 (Fmax) and speed of force development and force decay. Bar graphs show mean ± SEM from $n_{WT}=7$ and $n_{KO}=7$ mice. **E** Assessment of Ca²⁺-sensitivity by measurement of Ca²⁺-dependent force in permeabilized papillary muscle strips from Mfsd2b^{+/+} and Mfsd2b^{-/-} hearts. Curves are Hill fits to the mean data points. Mechanical measurements were performed on $n_{WT}=11$ and $n_{KO}=11$. Data is shown as mean ± SEM. Statistical analysis of data in bar graphs was performed using unpaired Student's *t* test, passive tension was analyzed using 2-way ANOVA with Sidak's multiple comparisons test. *p* values are as indicated above the compared data sets

be to protect the heart against deleterious calcium overload while preserving contractility. This would explain why Mfsd2b^{-/-} mice fared much better under AngII-induced cardiac remodeling in our study. In support of a more concentric type of hypertrophy taking place in Mfsd2b^{-/-} mice is the increased end-diastolic anterior and even more so posterior ventricular wall despite similar and rather small extent of fibrosis and identical

increase in natriuretic peptide expression. This would also be in agreement with lower LTCC activity being causally involved as any differences in calcium kinetics between ACM of both genotypes were abolished in the presence of verapamil. Indeed, enhanced calcium influx through LTCC has been shown to be responsible for cardiac hypertrophy and pathologic remodelling, and LTCC blockers effectively inhibit cardiac remodelling under

pressure overload [2, 37]. In line, phosphorylation of the PP2A target site Ser1981 in LTCC [4, 16] was clearly reduced by S1P-loading after isoprenaline stimulation. Finally, the phenotype of *Mfsd2b*^{-/-} was independent of blood pressure as both genotypes exhibited the same systolic blood pressure elevation with AngII.

We have previously shown that intracellular S1P directly activates PP2A in erythrocytes [58]. Among the myriad of physiological and pathophysiological processes PP2A regulates in cancer and diabetes, it also plays important roles in the heart, where it modulates calcium handling through its effects on ion channels, antiporters and pumps [31]. In particular, PP2A is a major negative regulator of LTCC activity and counteracts stimulation of voltage-gated calcium influx through LTCC after β -adrenergic stimulation [4]. In pacemaker cells, stimulation of PP2A by its upstream activator p21 activated kinase-1 (Pak1) repressed isoproterenol-stimulated LTCC activity [23]. Pak1 itself has been implicated in S1P-mediated inhibition of β -adrenergic stimulation of L-type calcium current [6] with intracellular S1P directly activating Pak 1 by a GTPase-independent mechanism thus bypassing its upstream regulatory proteins [1, 23]. Considering the abnormally high phosphorylation of LTCC and ryanodine receptors in heart failure, stimulation of PP2A activity has been suggested as a possible approach to restore the lost response to β -adrenergic stimulation in heart failure [31].

In the cancer field, small molecule activators of PP2A (SMAPs) as are currently being tested in clinical settings but must certainly be considered in cardiac diseases. Intriguingly, S1P analogs such as fingolimod (Gilenya[®]) have been known to inhibit PP2A quite some time through a mechanism involving displacement of PP2A's own inhibitors SET and ANP32A [15, 48]. In contrast, we have recently shown S1P directly binds to activates the catalytic PP2A subunit in erythrocytes [58]. Here, we have clearly seen enhanced PP2A activity in *Mfsd2b*-deficient hearts in vivo and after increasing intracellular S1P in ACM cardiomyocytes in vitro. There was no immunosuppression in global *Mfsd2b*-deficient mice which would be an advantage over the use of PP2A activators such as fingolimod. Thus, pharmacologic *Mfsd2b* inhibitors may be a novel approach to activate PP2A indirectly through intracellular S1P accumulation and, importantly, without the immunosuppressive side effects of extracellular S1P receptor downregulation by fingolimod. However, other phosphatases that could be activated by S1P and dephosphorylate LTCC might exist. Currently, the first pharmacologic inhibitors of *Mfsd2b* are being developed, and any success in using them to treat heart failure will open a new avenue of drug research for cardiac diseases.

Limitations

Although, *Mfsd2b*^{-/-} ACM exhibited a ~20% decrease in Ca²⁺ transients their sarcomere function was unchanged suggesting increased Ca²⁺ sensitivity of contractile proteins. However, neither did the calcium-sensitive proteins we looked at show any differences nor was muscle fiber force development altered. There was also no increase in cardiomyocyte passive stiffness (but rather a decrease instead) as another way cardiomyocytes employ to compensate for functional limitations caused by disturbed Ca²⁺ handling. We ruled out altered titin isoforms, ratios and post-translational modifications as reasons suggesting that other load-bearing cardiomyocyte structures such as actin, microtubules, and intermediate filaments might be altered in ways that influence cardiomyocyte passive stiffness. Outside of cardiomyocytes, ECM stiffness is known to determine the passive mechanical properties of muscle fibers. Whereas collagen content and cardiac fibrosis were unchanged in *Mfsd2b*^{-/-} hearts, collagen subtypes and/or crosslinks between ECM components that were not examined here may play a role. In addition, fibronectins, laminins and glycoproteins are also able to modify ECM stiffness. The exploration of the compensatory mechanisms that preserve contractility in *Mfsd2b*^{-/-} hearts is an exciting subject to be addressed in future studies.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00395-024-01073-x>.

Funding Open Access funding enabled and organized by Projekt DEAL. This project was supported financially by the Forschungskommission of the Medical Faculty of the Heinrich Heine University (Clinician Scientist Track No. 2022-01 to D.A.D.), the German Research Council (CRC 1116 Gerok to D.A.D.) and the German Research Council LE 940/7-1 (to B.L.), PO 2247/2-1 (to A.P.), and TRR259, project B10 (to B.L.).

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, Knaus UG (1998) A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. *J Biol Chem* 273:8137–8144. <https://doi.org/10.1074/jbc.273.14.8137>
- Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. *Circulation* 128:388–400. <https://doi.org/10.1161/CIRCULATIONAHA.113.001878>
- Cuspidi C, Sala C, Negri F, Mancina G, Morganti A (2012) Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. *J Hum Hypertens* 26:343–349. <https://doi.org/10.1038/jhh.2011.104>
- Davare MA, Horne MC, Hell JW (2000) Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase. *J Biol Chem* 275:39710–39717. <https://doi.org/10.1074/jbc.M005462200>
- Drazner MH (2011) The progression of hypertensive heart disease. *Circulation* 123:327–334. <https://doi.org/10.1161/CIRCULATIONAHA.108.845792>
- Egom EE, Bae JS, Capel R, Richards M, Ke Y, Pharithi RB, Maher V, Kruzliak P, Lei M (2016) Effect of sphingosine-1-phosphate on L-type calcium current and Ca(2+) transient in rat ventricular myocytes. *Mol Cell Biochem* 419:83–92. <https://doi.org/10.1007/s11010-016-2752-8>
- Eisner DA, Caldwell JL, Kistamás K, Trafford AW (2017) Calcium and excitation-contraction coupling in the heart. *Circ Res* 121:181–195. <https://doi.org/10.1161/CIRCRESAHA.117.310230>
- Eisner DA, Caldwell JL, Trafford AW, Hutchings DC (2020) The control of diastolic calcium in the heart. *Circ Res* 126:395–412. <https://doi.org/10.1161/CIRCRESAHA.119.315891>
- Erkens R, Kramer CM, Lückstädt W, Panknin C, Krause L, Weidenbach M, Dirzka J, Krenz T, Mergia E, Suvorava T, Kelm M, Cortese-Krott MM (2015) Left ventricular diastolic dysfunction in Nrf2 knock out mice is associated with cardiac hypertrophy, decreased expression of SERCA2a, and preserved endothelial function. *Free Radic Biol Med* 89:906–917. <https://doi.org/10.1016/j.freeradbiomed.2015.10.409>
- Fang R, Zhang LL, Zhang LZ, Li W, Li M, Wen K (2017) Sphingosine 1-phosphate postconditioning protects against myocardial ischemia/reperfusion injury in rats via mitochondrial signaling and akt-gsk3 β phosphorylation. *Arch Med Res* 48:147–155. <https://doi.org/10.1016/j.arcmed.2017.03.013>
- Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N (2012) The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. *J Clin Invest* 122:1416–1426. <https://doi.org/10.1172/jci60746>
- Funk F, Kronenbitter A, Isic M, Flocke V, Gorressen S, Semmler D, Brinkmann M, Beck K, Steinhoff O, Srivastava T, Barbosa DM, Voigt K, Wang L, Bottermann K, Kotter S, Grandoch M, Flögel U, Krüger M, Schmitt JP (2022) Diabetes disturbs functional adaptation of the remote myocardium after ischemia/reperfusion. *J Mol Cell Cardiol* 173:47–60. <https://doi.org/10.1016/j.yjmcc.2022.09.002>
- Gorski PA, Ceholski DK, Hajjar RJ (2015) Altered myocardial calcium cycling and energetics in heart failure—a rational approach for disease treatment. *Cell Metab* 21:183–194. <https://doi.org/10.1016/j.cmet.2015.01.005>
- Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL (2008) Ceramide starves cells to death by downregulating nutrient transporter proteins. *Proc Natl Acad Sci USA* 105:17402–17407. <https://doi.org/10.1073/pnas.0802781105>
- Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R, Hla T (2010) Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. *J Biol Chem* 285:26825–26831. <https://doi.org/10.1074/jbc.M110.147058>
- Hall DD, Feekes JA, Arachchige Don AS, Shi M, Hamid J, Chen L, Strack S, Zamponi GW, Horne MC, Hell JW (2006) Binding of protein phosphatase 2A to the L-type calcium channel Cav1.2 next to Ser 1928, its main PKA site, is critical for Ser1928 dephosphorylation. *Biochemistry* 45:3448–3459. <https://doi.org/10.1021/bi051593z>
- Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. *Lancet* 383:1933–1943. [https://doi.org/10.1016/s0140-6736\(14\)60107-0](https://doi.org/10.1016/s0140-6736(14)60107-0)
- Hill JA, Olson EN (2008) Cardiac plasticity. *N Engl J Med* 358:1370–1380. <https://doi.org/10.1056/NEJMra072139>
- Jin Z-Q, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS (2007) A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. *Cardiovasc Res* 76:41–50. <https://doi.org/10.1016/j.cardiores.2007.05.029>
- Józefczuk E, Nosalski R, Saju B, Crespo E, Szczepaniak P, Guzik TJ, Siedlinski M (2020) Cardiovascular effects of pharmacological targeting of sphingosine kinase 1. *Hypertension* 75:383–392. <https://doi.org/10.1161/HYPERTENSIONAHA.119.13450>
- Jujic A, Matthes F, Vanherle L, Petzka H, Orho-Melander M, Nilsson PM, Magnusson M, Meissner A (2021) Plasma S1P (sphingosine-1-phosphate) links to hypertension and biomarkers of inflammation and cardiovascular disease: findings from a translational investigation. *Hypertension* 78:195–209. <https://doi.org/10.1161/HYPERTENSIONAHA.120.17379>
- Juraszek B, Nalecz KA (2016) Protein phosphatase PP2A—a novel interacting partner of carnitine transporter OCTN2 (SLC22A5) in rat astrocytes. *J Neurochem* 139:537–551. <https://doi.org/10.1111/jnc.13777>
- Ke Y, Lei M, Solaro RJ (2008) Regulation of cardiac excitation and contraction by p21 activated kinase-1. *Prog Biophys Mol Biol* 98:238–250. <https://doi.org/10.1016/j.pbiomolbio.2009.01.007>
- Keul P, Sattler K, Levkau B (2007) HDL and its sphingosine-1-phosphate content in cardioprotection. *Heart Fail Rev* 12:301–306. <https://doi.org/10.1007/s10741-007-9038-x>
- Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA, van Loenen P, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravensloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schäfers M, Peters SL, Chun J, Levkau B (2016) Sphingosine-1-phosphate receptor 1 regulates cardiac function by modulating Ca²⁺ sensitivity and Na⁺/H⁺ exchange and mediates protection by ischemic preconditioning. *J Am Heart Assoc* 5:e003393. <https://doi.org/10.1161/jaha.116.003393>
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol* 8:e1000412. <https://doi.org/10.1371/journal.pbio.1000412>
- Kim SM, Roy SG, Chen B, Nguyen TM, McMonigle RJ, McCracken AN, Zhang Y, Kofuji S, Hou J, Selwan E, Finicle BT, Nguyen TT, Ravi A, Ramirez MU, Wiher T, Guenther GG, Kono M, Sasaki AT, Weisman LS, Potma EO, Tromberg BJ, Edwards RA, Hanessian S, Edinger AL (2016) Targeting cancer metabolism by simultaneously disrupting parallel nutrient access

- pathways. *J Clin Invest* 126:4088–4102. <https://doi.org/10.1172/JCI87148>
28. Kotter S, Gout L, Von Frieling-Salewsky M, Muller AE, Hellring S, Marcus K, Dos Remedios C, Linke WA, Kruger M (2013) Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. *Cardiovasc Res* 99:648–656. <https://doi.org/10.1093/cvr/cvt144>
 29. Kronenbitter A, Funk F, Hackert K, Gorreßen S, Glaser D, Boknik P, Poschmann G, Stühler K, Isić M, Krüger M, Schmitt JP (2018) Impaired Ca²⁺ cycling of nonischemic myocytes contributes to sarcomere dysfunction early after myocardial infarction. *J Mol Cell Cardiol* 119:28–39. <https://doi.org/10.1016/j.yjmcc.2018.04.004>
 30. Kruger M, Kohl T, Linke WA (2006) Developmental changes in passive stiffness and myofilament Ca²⁺ sensitivity due to titin and troponin-I isoform switching are not critically triggered by birth. *Am J Physiol Heart Circ Physiol* 291:H496–506. <https://doi.org/10.1152/ajpheart.00114.2006>
 31. Lei M, Wang X, Ke Y, Solaro RJ (2015) Regulation of Ca(2+) transient by PP2A in normal and failing heart. *Front Physiol* 6:13. <https://doi.org/10.3389/fphys.2015.00013>
 32. Levkau B (2008) Sphingosine-1-phosphate in the regulation of vascular tone. *Circ Res* 103:231–233. <https://doi.org/10.1161/CIRCRESAHA.108.181610>
 33. Loescher CM, Hobbach AJ, Linke WA (2022) Titin (TTN): from molecule to modifications, mechanics, and medical significance. *Cardiovasc Res* 118:2903–2918. <https://doi.org/10.1093/cvr/cvab328>
 34. Lorell BH, Carabello BA (2000) Left ventricular hypertrophy. *Circulation* 102:470–479. <https://doi.org/10.1161/01.CIR.102.4.470>
 35. Means CK, Brown JH (2009) Sphingosine-1-phosphate receptor signalling in the heart. *Cardiovasc Res* 82:193–200. <https://doi.org/10.1093/cvr/cvp086>
 36. Meissner A, Miro F, Jiménez-Altayó F, Jurado A, Vila E, Planas AM (2017) Sphingosine-1-phosphate signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension. *Cardiovasc Res* 113:123–133. <https://doi.org/10.1093/cvr/cvw256>
 37. Mendes AS, Blascke de Mello MM, Parente JM, Omoto ACM, Neto-Neves EM, Fazan R Jr, Tanus-Santos JE, Castro MM (2020) Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. *Life Sci* 244:117153. <https://doi.org/10.1016/j.lfs.2019.117153>
 38. Meyer zu Heringdorf D, Lass H, Kuchar I, Lipinski M, Alemany R, Rumenapp U, Jakobs KH (2001) Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors. *Eur J Pharmacol* 414:145–154. [https://doi.org/10.1016/s0014-2999\(01\)00789-0](https://doi.org/10.1016/s0014-2999(01)00789-0)
 39. Meyer zu Heringdorf D, Liliom K, Schaefer M, Danneberg K, Jaggar JH, Tigyi G, Jakobs KH (2003) Photolysis of intracellular caged sphingosine-1-phosphate causes Ca²⁺ mobilization independently of G-protein-coupled receptors. *FEBS Lett* 554:443–449. [https://doi.org/10.1016/s0014-5793\(03\)01219-5](https://doi.org/10.1016/s0014-5793(03)01219-5)
 40. Mills KT, Stefanescu A, He J (2020) The global epidemiology of hypertension. *Nat Rev Nephrol* 16:223–237. <https://doi.org/10.1038/s41581-019-0244-2>
 41. (NCD-RisC) NRFC (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet* 398:957–980. [https://doi.org/10.1016/s0140-6736\(21\)01330-1](https://doi.org/10.1016/s0140-6736(21)01330-1)
 42. Polzin A, Dannenberg L, Benkhoff M, Barcik M, Helten C, Mourikis P, Ahlbrecht S, Wildeis L, Ziese J, Zikeli D, Metzen D, Hu H, Baensch L, Schröder NH, Keul P, Weske S, Wollnitzke P, Duse D, Saffak S, Cramer M, Bönner F, Müller T, Gräler MH, Zeus T, Kelm M, Levkau B (2023) Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction. *Nat Commun* 14:2404. <https://doi.org/10.1038/s41467-023-38069-5>
 43. Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Ayhan A, Weske S, Ahlbrecht S, Trojovský K, Helten C, Haberkorn S, Flögel U, Zeus T, Müller T, Gräler MH, Kelm M, Levkau B (2023) Sphingosine-1-phosphate improves outcome of no-reflow acute myocardial infarction via sphingosine-1-phosphate receptor 1. *ESC Heart Fail* 10:334–341. <https://doi.org/10.1002/ehf2.14176>
 44. Polzin A, Piayda K, Keul P, Dannenberg L, Mohring A, Gräler M, Zeus T, Kelm M, Levkau B (2017) Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease. *J Mol Cell Cardiol* 110:35–37. <https://doi.org/10.1016/j.yjmcc.2017.07.004>
 45. Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Helten C, Zeus T, Kelm M, Levkau B (2022) S1P lyase inhibition starting after ischemia/reperfusion improves postischemic cardiac remodeling. *JACC Basic Transl Sci* 7:498–499. <https://doi.org/10.1016/j.jacmts.2022.03.009>
 46. Reventun P, Sánchez-Esteban S, Cook-Calvete A, Delgado-Marín M, Roza C, Jorquera-Ortega S, Hernandez I, Tesoro L, Botana L, Zamorano JL, Zaragoza C, Saura M (2023) Endothelial ILK induces cardioprotection by preventing coronary microvascular dysfunction and endothelial-to-mesenchymal transition. *Basic Res Cardiol* 118:28. <https://doi.org/10.1007/s00395-023-00997-0>
 47. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, Berrebi-Bertrand I (2001) EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. *J Mol Cell Cardiol* 33:1589–1606. <https://doi.org/10.1006/jmcc.2001.1433>
 48. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B (2013) Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. *EMBO Mol Med* 5:105–121. <https://doi.org/10.1002/emmm.201201283>
 49. Santulli G, Xie W, Reiken SR, Marks AR (2015) Mitochondrial calcium overload is a key determinant in heart failure. *Proc Natl Acad Sci USA* 112:11389–11394. <https://doi.org/10.1073/pnas.1513047112>
 50. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Gräler MH, Bröcker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B (2010) Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. *Basic Res Cardiol* 105:821–832. <https://doi.org/10.1007/s00395-010-0112-5>
 51. Sattler K, Levkau B (2009) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. *Cardiovasc Res* 82:201–211. <https://doi.org/10.1093/cvr/cvp070>
 52. Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, Asahi M, MacLennan DH, Seidman CE, Seidman JG, Lohse MJ (2009) Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca²⁺-ATPase inhibition. *Circulation* 119:436–444. <https://doi.org/10.1161/circulationaha.108.783506>
 53. Siedlinski M, Nosalski R, Szczepaniak P, Ludwig-Gałęzowska AH, Mikołajczyk T, Filip M, Osmenda G, Wilk G, Nowak M, Wołkow P, Guzik TJ (2017) Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. *Sci Rep* 7:44131. <https://doi.org/10.1038/srep44131>
 54. Spiegel S, Milstien S (2003) Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by

- divergent pathways. *Biochem Soc Trans* 31:1216–1219. <https://doi.org/10.1042/bst0311216>
55. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. *Adv Exp Med Biol* 688:141–155. https://doi.org/10.1007/978-1-4419-6741-1_10
56. Subbaiah KCV, Wu J, Tang WHW, Yao P (2022) FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling. *JCI Insight*. <https://doi.org/10.1172/jci.insight.152783>
57. Suthahar N, Meijers WC, Silljé HHW, de Boer RA (2017) From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. *Curr Heart Fail Rep* 14:235–250. <https://doi.org/10.1007/s11897-017-0343-y>
58. Thomas N, Schroder NH, Nowak MK, Wollnitzke P, Ghaderi S, von Wnuck LK, Wille A, Deister-Jonas J, Vogt J, Graler MH, Dannenberg L, Buschmann T, Westhoff P, Polzin A, Kelm M, Keul P, Weske S, Levkau B (2023) Sphingosine-1-phosphate suppresses GLUT activity through PP2A and counteracts hyperglycemia in diabetic red blood cells. *Nat Commun* 14:8329. <https://doi.org/10.1038/s41467-023-44109-x>
59. Umbarkar P, Ejantkar S, Ruiz Ramirez SY, Toro Cora A, Zhang Q, Tousif S, Lal H (2023) Cardiac fibroblast GSK-3 α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis. *Basic Res Cardiol* 118:35. <https://doi.org/10.1007/s00395-023-01005-1>
60. Vessey DA, Kelley M, Li L, Huang Y, Zhou HZ, Zhu BQ, Karliner JS (2006) Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. *Med Sci Monit* 12:Br318–Br324
61. Vessey DA, Li L, Honbo N, Karliner JS (2009) Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. *Am J Physiol Heart Circ Physiol* 297:H1429–H1435. <https://doi.org/10.1152/ajpheart.00358.2009>
62. Vu TM, Ishizu AN, Foo JC, Toh XR, Zhang F, Whee DM, Torta F, Cazenave-Gassiot A, Matsumura T, Kim S, Toh SES, Suda T, Silver DL, Wenk MR, Nguyen LN (2017) Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. *Nature* 550:524–528. <https://doi.org/10.1038/nature24053>
63. Xue Y, Jiang W, Ma Q, Wang X, Jia P, Li Q, Chen S, Song B, Wang Y, Zhang J, Liu J, Yang G, Lin Y, Liu J, Wei L, Dong C, Li H, Xie Z, Bai L, Ma A (2020) U-shaped association between plasma sphingosine-1-phosphate levels and mortality in patients with chronic systolic heart failure: a prospective cohort study. *Lipids Health Dis* 19:125. <https://doi.org/10.1186/s12944-020-01262-2>